Barclays says reports of Eli Lilly (LLY) reportedly being in talks to acquire Scorpion Therapeutics has a positive read-through to Relay ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...